Please assess the completion status of the following clinical trial:

Trial Title: Fluid Responsiveness Evaluation in Sepsis-associated Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of sepsis, as exhibited by 2 or more of the following systemic inflammatory response syndrome (SIRS) criteria and a known or presumed infection at time of screening:~   * Temperature of \> 38 C or \< 36 C~  * Heart rate of \> 90/min~  * Respiratory rate of \> 20/min or PaCO2 \< 32 mm Hg (4.3 kPA)~  * White blood cell count \> 12000/mm3 or \< 4000/mm3 or \>10% immature bands~2. Refractory hypotension despite initial fluid resuscitation (1L of treatment fluid)~3. Patient enrolled in study as soon as possible (ideal window of 0-12 hours) and within 24 hours of arrival to the hospital~4. Anticipated ICU admission~5. Able to provide signed informed consent or consent can be obtained from the patient's authorized representative~Exclusion Criteria:~1. Primary diagnosis of: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, drug overdose, or injury from burn or trauma~2. Known aortic insufficiency, or aortic abnormalities~3. Hemodynamic instability due to active gastrointestinal hemorrhage~4. Patient has received \>3 liters of IV fluid prior to study randomization~5. Requires immediate surgery~6. Patient transferred to the ICU from another hospital unit~7. Do not attempt resuscitation (DNAR or DNR) order~8. Advanced directives restricting implementation of the resuscitation protocol~9. Contraindication to blood transfusion~10. Attending clinician deems aggressive resuscitation unsuitable~11. Transferred from another in-hospital setting~12. Not able to commence treatment protocol within 1 hour after randomization~13. Known intraventricular heart defect, such as ventral septal defect or atrial septal defect~14. Use of additional hemodynamic monitoring involving stroke volume variation (SVV) to determine fluid responsiveness~15. Seizure in the last 24 hours~16. Prisoner~17. Pregnancy~18. Age \<18~19. Known allergy to sensor material or gel~20. Inability or contraindication to doing a passive leg raise with both extremities, such as inability to interrupt venous compression boots~21. Patient has an epidural catheter in place~22. Suspected intra-abdominal hypertension~23. Inability to obtain IV access~24. Diabetic ketoacidosis~25. Hyper-osmolarity syndrome~26. Patient uncouples from treatment algorithm~27. Patient should be excluded based on the opinion of the Clinician/Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Starling SV monitor (Type: EXPERIMENTAL): A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of \< 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
- Control (Type: NO_INTERVENTION): No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete